Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 9/20 | 0.34 |
| ▸ | MAOA | P21397 | 8/20 | 0.34 |
| ▸ | KDM1A | O60341 | 6/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4390692 | 0.76 | HTR2A (0.42) | HTR2AOPRM1MAOBMAOADRD4 | |
| SCHEMBL4391087 | 0.66 | HTR2A (0.48) | CYP2D6HTR2ASMN1; SMN2OPRM1DRD4 | |
| SCHEMBL16707834 | 0.64 | L3MBTL1 (0.43) | CYP2D6SMN1; SMN2OPRM1MAOBMAOA | |
| SCHEMBL16707822 | 0.64 | L3MBTL1 (0.43) | CYP2D6SMN1; SMN2OPRM1MAOBMAOA | |
| SCHEMBL23376752 | 0.63 | ALPL (0.30) | — | |
| SCHEMBL12428091 | 0.63 | — | — | |
| SCHEMBL765950 | 0.63 | — | — | |
| SCHEMBL25978080 | 0.63 | ALPL (0.30) | — | |
| SCHEMBL17666180 | 0.63 | SMN1; SMN2 (0.44) | CYP2D6SMN1; SMN2OPRM1DRD4 | |
| SCHEMBL11463005 | 0.63 | CYP2D6 (0.42) | CYP2D6HTR2ASMN1; SMN2OPRM1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017441-B2 | Direct anti-markovnikov addition of acids to alkenes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017441-B2 | Direct anti-markovnikov addition of acids to alkenes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-07-10 | — | — | US | disclosed |
| US-20160096791-A1 | DIRECT ANTI-MARKOVNIKOV ADDITION OF ACIDS TO ALKENES | UNIV NORTH CAROLINA (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096791-A1 | DIRECT ANTI-MARKOVNIKOV ADDITION OF ACIDS TO ALKENES | UNIV NORTH CAROLINA (US) | 2016-04-07 | — | — | US | disclosed |
| WO-2014179648-A2 | DIRECT ANTI-MARKOVNIKOV ADDITION OF ACIDS TO ALKENES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014179648-A2 | DIRECT ANTI-MARKOVNIKOV ADDITION OF ACIDS TO ALKENES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096791-A1 | DIRECT ANTI-MARKOVNIKOV ADDITION OF ACIDS TO ALKENES | HAO2, DUOX2, PDK2 | CYP2D6 165/4885HTR2A 3115/4885SMN1; SMN2 2623/4885 |
| US-10017441-B2 | Direct anti-markovnikov addition of acids to alkenes | HAO2, DUOX2, PDK2 | CYP2D6 165/4885HTR2A 3115/4885SMN1; SMN2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.